Jefferies resumed coverage on Viatris with a new price target
$VTRS
Biotechnology: Pharmaceutical Preparations
Health Care
Jefferies resumed coverage of Viatris with a rating of Hold and set a new price target of $11.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/19/2024 | $15.00 | Buy | Jefferies |
| 10/23/2023 | $13.00 → $9.00 | Neutral → Underperform | BofA Securities |
| 6/23/2023 | $11.00 | Equal Weight → Underweight | Barclays |
| 4/24/2023 | $11.00 | Overweight → Equal Weight | Barclays |
| 2/17/2023 | $16.00 → $14.00 | Outperform → Market Perform | BMO Capital Markets |
| 1/27/2023 | $13.00 → $15.00 | Hold → Buy | Jefferies |
| 11/10/2022 | $9.00 → $12.00 | Sell → Neutral | UBS |
| 11/8/2022 | $10.00 | Underweight → Neutral | Piper Sandler |
4 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)
PITTSBURGH, March 28, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) will report first quarter 2025 financial results on Thursday, May 8, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthc
PITTSBURGH, Feb. 27, 2025 /PRNewswire/ -- Meets 2024 Guidance for Total Revenues, Adjusted EBITDA and Adjusted EPS; Exceeds 2024 Guidance for Free Cash Flow [1]Reports 2024 Total Revenues of $14.7 Billion, U.S. GAAP Net Loss of $(634) Million, Adjusted EBITDA of $4.7 Billion, U.S. GAAP Diluted EPS Loss of $(0.53) per Share, Adjusted EPS of $2.65 per Share, U.S. GAAP Net Cash Provided by Operating Activities of $2.3 Billion, and Free Cash Flow of $2.0 Billion Including ~$650 Million of Transaction-Related CostsDelivers Strong New Product Revenues of $582 Million in 2024Returns $825 Million in Capital to Shareholders and Repays $3.7 Billion of Debt in 2024An
PITTSBURGH, Feb. 27, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that on February 24, 2025, its Board of Directors approved a 2025 dividend policy of 48 cents ($0.48) per share and declared a quarterly dividend of 12 cents ($0.12) for each issued and outstanding share of the Company's common stock. The dividend is payable on March 18, 2025, to shareholders of record at the close of business on March 10, 2025. This marks the fifth consecutive year the Company has paid a dividend. About ViatrisViatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistic
Jefferies resumed coverage of Viatris with a rating of Buy and set a new price target of $15.00
BofA Securities downgraded Viatris from Neutral to Underperform and set a new price target of $9.00 from $13.00 previously
Barclays downgraded Viatris from Equal Weight to Underweight and set a new price target of $11.00
PITTSBURGH, April 25, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, will present at the BofA Securities 2025 Healthcare Conference in Las Vegas, NV, on Tuesday, May 13, 2025. The company's presentation will begin at 5 p.m. PT / 8 p.m. ET. A live webcast of the event at can be found at investor.viatris.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time. About ViatrisViatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthc
Aiming to address a significant unmet need for which no other approved treatment option is available for generalized anxiety disorder patients in Japan PITTSBURGH, April 21, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced it has filed applications to the Ministry of Health, Labor and Welfare (MHLW) for approval of Effexor SR Capsules (venlafaxine hydrochloride), a serotonin-noradrenaline reuptake inhibitor (SNRI) to treat adults with generalized anxiety disorder (GAD), an indication for which no other treatment option is currently approved in Japan. As previously announced, our Phase 3 placebo-controlled, randomized, double-blind, multicenter stu
PITTSBURGH, April 14, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that Hemanth J. Varghese has joined the Company as Chief Strategy Officer. Varghese will be a member of the Company's Executive Leadership Team. Varghese is an accomplished healthcare leader with more than 20 years of strategy, operations and corporate development experience. He brings broad experience leading growth initiatives and strategic transformations in diversified multi-national healthcare companies. Prior to joining Viatris, Varghese was President and Chief Operating Officer at Venu
PITTSBURGH, April 14, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that Hemanth J. Varghese has joined the Company as Chief Strategy Officer. Varghese will be a member of the Company's Executive Leadership Team. Varghese is an accomplished healthcare leader with more than 20 years of strategy, operations and corporate development experience. He brings broad experience leading growth initiatives and strategic transformations in diversified multi-national healthcare companies. Prior to joining Viatris, Varghese was President and Chief Operating Officer at Venu
PITTSBURGH, June 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that as part of its ongoing Board refreshment efforts, Rogerio Vivaldi Coelho, M.D., has been appointed as the newest member of its Board of Directors. Dr. Vivaldi will serve as a member of the recently reestablished Science and Technology Committee of the Board of Directors. "We are pleased to welcome Dr. Vivaldi to our Board of Directors," said Melina Higgins, Chair of the Board, Viatris. "We believe his proven expertise and long track record of success will enhance the efforts of the Board across a range of areas, in particular with regards to our Science and Technology Commit
PITTSBURGH, April 15, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company's Executive Leadership Team, effective today. Le Goff is an accomplished biotechnology and pharmaceutical executive with more than 25 years of experience leading and building highly successful teams globally. She is a visionary and entrepreneurial leader with a strong scientific background and experience across multiple markets and therapeutic areas. Prior to joining Viatris, Le Goff was President and Chief Executive Officer of Imunon, a clinical-stage biotechnology
10-K - Viatris Inc (0001792044) (Filer)
8-K - Viatris Inc (0001792044) (Filer)
SCHEDULE 13G - Viatris Inc (0001792044) (Subject)
4 - Viatris Inc (0001792044) (Issuer)
SC 13G/A - Viatris Inc (0001792044) (Subject)
SC 13G/A - Viatris Inc (0001792044) (Subject)
SC 13G - Viatris Inc (0001792044) (Subject)